Microcide Pharmaceuticals Announces Licensing Agreement With Aurora Biosciences

Apr 26, 2001, 01:00 ET from Microcide Pharmaceuticals, Inc.

    MOUNTAIN VIEW, Calif., April 26 /PRNewswire/ --
 Microcide Pharmaceuticals, Inc. (Nasdaq:   MCDE) today announced that it has
 entered into a licensing agreement with
 Aurora Biosciences Corporation (Nasdaq:   ABSC) in which Aurora will obtain a
 non-exclusive license to Microcide's U.S. Patent Number 6,020,121, "Inhibitors
 of Regulatory Pathways", related to a specific non-traditional bacterial
 target.  Microcide has also agreed to provide certain materials necessary for
 screening with this target.
     The technology base which generated this patent is Microcide's VALID
 (Validated Antimicrobial Lead Identification and Development) System, an
 integrated, genomics-driven approach to the discovery and development of new
 classes of antibiotics, antifungal agents and antiviral drugs.  Utilizing the
 VALID System, Microcide has identified a broad-spectrum antifungal compound
 series, which has advanced into lead optimization.
     "While other companies have constructed some target-to-drug capabilities,
 at Microcide we have uniquely integrated a powerful collection of proprietary
 technology in the VALID System to identify and prove that compounds active
 against the desired target can enter the microbe, reach the target, and kill
 the pathogen," said Jim Rurka, President and Chief Executive Officer of
 Microcide.  "We then have the full capability to advance these discoveries
 through drug development and into clinical trials."
     Rurka added, "The target licensed to Aurora is one of the more than
 350 validated microbial targets derived from the VALID System, of which more
 than 100 currently have patents issued or pending.  We are aggressively
 developing this complete package of discovery and development capabilities to
 discover compounds for our own account, and also plan to partner with other
 antimicrobial-committed companies."
 
     Summary of VALID:
     -- Microcide has discovered over 350 validated, pharmaceutically-relevant
        microbial gene targets in Gram-positive and Gram-negative bacteria,
        fungi and viruses for drug discovery.  A large number of these are
        proprietary to the Company.
     -- Microcide has a Selected Diversity Library of 250,000 compounds
        (synthetic, natural product and combinatorial), and an assay
        development and High Throughput Screening (HTS) group able to apply its
        novel targets and diversity to drug discovery.
     -- Once leads are identified, the Company has the proven ability to
        advance compounds into a fully-integrated process of medicinal
        chemistry, microbiology and pharmacology -- to successfully achieve
        pre-clinical development candidates.
 
     Microcide is a biopharmaceutical company committed to the discovery,
 development and commercialization of novel antimicrobials for the improved
 treatment of serious bacterial, fungal and viral infections.  The Company's
 three discovery research platforms address the growing problems of antibiotic
 resistance and the need for improved antifungal and antiviral therapeutics.
 The Company's Cephalosporin Antibiotics and Efflux Pump Inhibition platforms
 focus on developing novel antibiotics and antibiotic potentiators
 (efflux inhibitors) to directly address existing bacterial and fungal
 resistance problems.  Microcide's Microbial Genomics platform utilizes
 proprietary bacterial, fungal and viral genetics and genomics tools -- the
 VALID System -- to discover entirely new classes of antimicrobial agents.
 
     Aurora Biosciences(R) is a drug discovery company that uses proprietary
 advances in biology, chemistry and automation to accelerate the discovery of
 new medicines.  Aurora's core technologies include a broad portfolio of
 proprietary fluorescence assay technologies and screening platforms designed
 to provide an integrated solution for drug discovery.  Aurora's fluorescence
 assay technologies include GeneBLAzer(TM), GenomeScreen(TM),
 PhosphoryLIGHT(TM) and Vivid(TM) technologies, as well as a broad collection
 of fluorescent proteins.  Aurora's screening platforms include an ultra-high
 throughput screening system, the UHTSS(R) Platform, Aurora's automated master
 compound store, the AMCS, and an ion channel technology screening platform,
 which includes Aurora's proprietary voltage sensor probes and a voltage ion
 probe reader, the VIPR(TM) subsystem.  Aurora also provides assay development
 and screening services as part of its drug discovery collaborations.  Aurora's
 Big Biology(TM) initiative is an internal drug discovery program focused on
 the identification of promising preclinical candidates within all major
 classes of gene targets.  Aurora's technologies and drug discovery
 capabilities have been commercially validated by over 20 major life sciences
 companies and research organizations, including American Home Products,
 Bristol-Myers Squibb, Ceres, Cystic Fibrosis Foundation, Eli Lilly,
 Families of SMA, GlaxoSmithKline, Genentech, Johnson & Johnson, Merck,
 NV Organon Laboratories, Pfizer, Pharmacia and Roche.  For additional
 information on Aurora's services and products, please contact Sales and
 Marketing via email at marcom@aurorabio.com.
 
     The statements in this press release that relate to Microcide developing
 new antimicrobials are forward-looking statements.  Such forward-looking
 statements involve risks and uncertainties including, without limitation, the
 following.  There is no assurance that any compounds discovered using the
 VALID System will successfully proceed through pre-clinical development and
 clinical trials, obtain requisite regulatory approvals for marketing or result
 in a commercially useful product.  There is no assurance that the Company will
 successfully continue existing corporate collaborations or enter into further
 collaborations with respect to any of its internally funded research programs
 or that current collaborators will elect to proceed through the various stages
 of clinical development as currently anticipated or on the same schedule as we
 would proceed if we were conducting such trials independently.  For a
 discussion of other risks and uncertainties affecting Microcide's business,
 see the Company's annual report on Form 10-K/A for the year ended
 December 31, 2000 and Form S-3 shelf registration statement filed on
 February 9, 2001, as amended on March 21, 2001.  Actual results and timing of
 certain events could differ materially from those indicated in the
 forward-looking statements as a result of these or other factors.
 
     CONTACT:  Investors, Donald D. Huffman, VP of Finance and Corporate
 Development and CFO of Microcide Pharmaceuticals, Inc., 650-428-3557.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X40305196
 
 

SOURCE Microcide Pharmaceuticals, Inc.
    MOUNTAIN VIEW, Calif., April 26 /PRNewswire/ --
 Microcide Pharmaceuticals, Inc. (Nasdaq:   MCDE) today announced that it has
 entered into a licensing agreement with
 Aurora Biosciences Corporation (Nasdaq:   ABSC) in which Aurora will obtain a
 non-exclusive license to Microcide's U.S. Patent Number 6,020,121, "Inhibitors
 of Regulatory Pathways", related to a specific non-traditional bacterial
 target.  Microcide has also agreed to provide certain materials necessary for
 screening with this target.
     The technology base which generated this patent is Microcide's VALID
 (Validated Antimicrobial Lead Identification and Development) System, an
 integrated, genomics-driven approach to the discovery and development of new
 classes of antibiotics, antifungal agents and antiviral drugs.  Utilizing the
 VALID System, Microcide has identified a broad-spectrum antifungal compound
 series, which has advanced into lead optimization.
     "While other companies have constructed some target-to-drug capabilities,
 at Microcide we have uniquely integrated a powerful collection of proprietary
 technology in the VALID System to identify and prove that compounds active
 against the desired target can enter the microbe, reach the target, and kill
 the pathogen," said Jim Rurka, President and Chief Executive Officer of
 Microcide.  "We then have the full capability to advance these discoveries
 through drug development and into clinical trials."
     Rurka added, "The target licensed to Aurora is one of the more than
 350 validated microbial targets derived from the VALID System, of which more
 than 100 currently have patents issued or pending.  We are aggressively
 developing this complete package of discovery and development capabilities to
 discover compounds for our own account, and also plan to partner with other
 antimicrobial-committed companies."
 
     Summary of VALID:
     -- Microcide has discovered over 350 validated, pharmaceutically-relevant
        microbial gene targets in Gram-positive and Gram-negative bacteria,
        fungi and viruses for drug discovery.  A large number of these are
        proprietary to the Company.
     -- Microcide has a Selected Diversity Library of 250,000 compounds
        (synthetic, natural product and combinatorial), and an assay
        development and High Throughput Screening (HTS) group able to apply its
        novel targets and diversity to drug discovery.
     -- Once leads are identified, the Company has the proven ability to
        advance compounds into a fully-integrated process of medicinal
        chemistry, microbiology and pharmacology -- to successfully achieve
        pre-clinical development candidates.
 
     Microcide is a biopharmaceutical company committed to the discovery,
 development and commercialization of novel antimicrobials for the improved
 treatment of serious bacterial, fungal and viral infections.  The Company's
 three discovery research platforms address the growing problems of antibiotic
 resistance and the need for improved antifungal and antiviral therapeutics.
 The Company's Cephalosporin Antibiotics and Efflux Pump Inhibition platforms
 focus on developing novel antibiotics and antibiotic potentiators
 (efflux inhibitors) to directly address existing bacterial and fungal
 resistance problems.  Microcide's Microbial Genomics platform utilizes
 proprietary bacterial, fungal and viral genetics and genomics tools -- the
 VALID System -- to discover entirely new classes of antimicrobial agents.
 
     Aurora Biosciences(R) is a drug discovery company that uses proprietary
 advances in biology, chemistry and automation to accelerate the discovery of
 new medicines.  Aurora's core technologies include a broad portfolio of
 proprietary fluorescence assay technologies and screening platforms designed
 to provide an integrated solution for drug discovery.  Aurora's fluorescence
 assay technologies include GeneBLAzer(TM), GenomeScreen(TM),
 PhosphoryLIGHT(TM) and Vivid(TM) technologies, as well as a broad collection
 of fluorescent proteins.  Aurora's screening platforms include an ultra-high
 throughput screening system, the UHTSS(R) Platform, Aurora's automated master
 compound store, the AMCS, and an ion channel technology screening platform,
 which includes Aurora's proprietary voltage sensor probes and a voltage ion
 probe reader, the VIPR(TM) subsystem.  Aurora also provides assay development
 and screening services as part of its drug discovery collaborations.  Aurora's
 Big Biology(TM) initiative is an internal drug discovery program focused on
 the identification of promising preclinical candidates within all major
 classes of gene targets.  Aurora's technologies and drug discovery
 capabilities have been commercially validated by over 20 major life sciences
 companies and research organizations, including American Home Products,
 Bristol-Myers Squibb, Ceres, Cystic Fibrosis Foundation, Eli Lilly,
 Families of SMA, GlaxoSmithKline, Genentech, Johnson & Johnson, Merck,
 NV Organon Laboratories, Pfizer, Pharmacia and Roche.  For additional
 information on Aurora's services and products, please contact Sales and
 Marketing via email at marcom@aurorabio.com.
 
     The statements in this press release that relate to Microcide developing
 new antimicrobials are forward-looking statements.  Such forward-looking
 statements involve risks and uncertainties including, without limitation, the
 following.  There is no assurance that any compounds discovered using the
 VALID System will successfully proceed through pre-clinical development and
 clinical trials, obtain requisite regulatory approvals for marketing or result
 in a commercially useful product.  There is no assurance that the Company will
 successfully continue existing corporate collaborations or enter into further
 collaborations with respect to any of its internally funded research programs
 or that current collaborators will elect to proceed through the various stages
 of clinical development as currently anticipated or on the same schedule as we
 would proceed if we were conducting such trials independently.  For a
 discussion of other risks and uncertainties affecting Microcide's business,
 see the Company's annual report on Form 10-K/A for the year ended
 December 31, 2000 and Form S-3 shelf registration statement filed on
 February 9, 2001, as amended on March 21, 2001.  Actual results and timing of
 certain events could differ materially from those indicated in the
 forward-looking statements as a result of these or other factors.
 
     CONTACT:  Investors, Donald D. Huffman, VP of Finance and Corporate
 Development and CFO of Microcide Pharmaceuticals, Inc., 650-428-3557.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X40305196
 
 SOURCE  Microcide Pharmaceuticals, Inc.

RELATED LINKS

http://www.microcide.com